Des-gamma-carboxy prothrombin (DCP) Test

Des-gamma-carboxy prothrombin (DCP), also known as PIVKA II (protein induced by vitamin K absence or antagonists II), is an abnormal form of prothrombin, a clotting factor produced by the liver.

By measuring the amount of DCP in the blood, the test helps evaluate whether treatment for hepatocellular carcinoma (HCC), a type of liver cancer, is effective.


For a person diagnosed with HCC, an increasing DPC level means that the cancer is producing this substance. In this sense, the test can be used as a tumor marker. As the test is typically ordered periodically, changes over time can also be evaluated.

  • Decreasing DPC levels in a person who is being treated for HCC suggest response to treatment.
  • Steady or increasing levels after treatment indicate that the treatment has not been effective.
  • Increasing levels after treatment has been completed suggest recurrence of HCC.

Things you must keep in mind:

A person can have HCC even with steady or decreasing DCP. The tumor may not produce DCP or it may be small enough that it is not producing significant amounts.

Keywords: Des-gamma-carboxy prothrombin; DCP; PIVKA II; prothrombin; liver cancer

* The contents of this HTQ Site are for informational and communicational purposes only. The information provided by HTQ, HTQ employees, others appearing on the Site at the invitation of HTQ, or other visitors to the Site is NOT a medical advice.The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on the HTQ Site!